Ten healthy volunteers received 1 g of BRL-36650, a new formamido-penicillin derivative, given by intravenous infusion over 15 min. Levels in serum were measured microbiologically 30, 60, and 120 min after the start of the 15-min infusion and were (mean ± standard deviation) 102.7 ± 28.4, 59.7 ± 11.5, and 9.6 ± 1.9 mg/liter, respectively. A total of 10 strains each of Escherichia coli, Klebsiella pneumoniae, Serratia spp Severe gram-negative bacillary infection remains a major problem in patients with cancer, especially in neutropenic patients (11).
Severe gram-negative bacillary infection remains a major problem in patients with cancer, especially in neutropenic patients (11) .
The recent introduction of a number of new broadspectrum penicillins and cephalosporins has generated increased interest in the management of these infections (5, 8) .
BRL-36650, a 6-a-formamido-penicillin derivative, has been reported to be highly active against aerobic gramnegative bacteria and stable to beta-lactamases produced by these organisms (2) .
In the present study, we studied the in vitro activity of BRL-36650 against clinical isolates of gram-negative bacteria. We also evaluated the efficacy, as measured by the titration of the serum bactericidal activity (SBA), and the rate of bactericidal activity in serum of parenteral BRL-36650 administered to volunteers against selected gram-negative pathogens.
MATERIALS AND METHODS
Antibiotics. BRL-36650 was kindly provided by Beecham Pharmaceuticals, European Division, and piperacillin was from Lederle-Cyanamid.
Organisms. A total of 10 strains each of Escherichia coli (7 susceptible to piperacillin, MIC, 64 mg/liter; 3 resistant to piperacillin, MIC, >64 mg/liter), Klebsiella pneumoniae (7  susceptible and 3 (6) , taking into account the actual mean inoculum, a double sampling of 4 ,ul, and a total error on the volume and the initial inoculum estimation of 25%. This corresponded to 99.9% killing, with a sensitivity of 99.9% and a specificity of 99.7% (12) .
Volunteers. Ten healthy volunteers (five women, five men; mean height, 1.75 m; range, 1.60 to 1.89 m; mean weight, 72 kg, range, 54 to 92 kg) were entered into the study after informed consent was obtained. Prior to the study the following blood tests were done: leukocyte, erythrocyte, hematocrit, hemoglobin, differential formula, ionogram, aspartate-and alanine-amino transferases, alkaline phosphatases, lactate dehydrogtnase, total bilirubin, urea, creatinine, and uric acid. These tests were not performed after the study in the absence of clinically apparent side effects.
Administration of antibiotic. Each volunteer received 1 g of BRL-36650, diluted in saline, given by a short (15-min) intravenous infusion. Blood samples were taken at 30 min, 1 h, and 4 h after the start of infusion. The serum was separated from clotted blood and immediately stored at (9) . Median MBCs of piperacillin-resistant strains of K. pneumoniae, Enterobacter spp., Serriatia spp., and P. aeruginosa were higher than those of piperacillin-susceptible strains either in broth or in 50% broth-serum.
Clinical adverse effects were not observed after intravenous administration of BRL-36650 to volunteers. The serum levels are shown in Table 2 .
The serum bacteriostatic activity and SBA are listed in Table 3 . High bacteriostatic activities were observed against all species tested. In the case of E. coli and K. pneumoniae, median SBAs were .1:2,048 and 1:512, respectively. Median SBAs against Enterobacter spp., Serratia spp., and P. aeruginosa susceptible to piperacillin were excellent, with 94 to 100% of sera providing SBAs -1:8. When sera were tested against piperacillin-resistant Enterobacter spp. and Serratia spp., SBAs were lower than those of susceptible strains (1:8 and 1:64, respectively). Against piperacillinresistant P. aeruginosa, the median SBA was 1:4, with only 43% of sera providing a SBA -1:8.
In Fig. 1 is summarized the data on the killing rates. The high rate of killing observed against a strain of Serratia spp. (Fig. 1A) is representative for all the tested organisms, except for one strain of Enterobacter spp. (Fig. 1B) and one strain of P. aeruginosa (Fig. IC) , both of which were resistant to piperacillin, for which the MBCs in the presence of 50% human serum were .32 mg/liter. DISCUSSION All strains tested were found to be susceptible to BRL-36650 in vitro. Peak serum concentrations were 7-to 100-fold higher than the MICs obtained in agar. The MICs in 50% human serum were lower than the MICs in broth, and the MBCs were very close to the MICs in both media, with the exception of a few strains for which the MBC/MIC ratios in 50% serum-broth were very high.
The SBA has been shown to predict the outcome of bacteremic infections in cancer patients (10) . The sera of volunteers receiving 1 g of BRL-36650 provided good bactericidal activities against the majority of strains tested. Nevertheless, the SBA was significantly lower for piperacillin-resistant strains of Serratia spp., Enterobacter spp., and P. aeruginosa than for piperacillin-susceptible strains. The increased MBCs of piperacillin-resistant strains, particularly in the case of P. aeruginosa in the presence of human serum, could explain these differences. Although the low protein binding of BRL-36650, which is 30% (Beecham Pharmaceuticals Research Division, unpublished data), cannot explain the difference in in vitro susceptibility between serum and serum-broth. Taking into account the serum levels, the bactericidal activity would probably be augmented with higher dosages of BRL-36650. Doses of up to 4.0 g were given to healthy volunteers without any trouble. Peak serum concentrations were found to be proportional to the given dose being respectively 57.8, 110.6, 224.7 and 427.0 mg/liter after 0.5, 1.0, 2.0, and 4.0 g, respectively, was administered as a 3-min intravenous bolus injection in 10 volunteers (Beecham Pharmaceuticals Research Division, unpublished data).
In conclusion, the high in vitro activity and its effective bactericidal activity after administration to volunteers make BRL-36650 a candidate for the treatment of gram-negative bacillary infections, and clinical trials are warranted. 
